secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0000950170-22-003382
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports Q3 net loss $22.5M; KVD900 Phase 3 trial initiated, data expected H2 2023
--------------------------------------------------------------------------------

- Net loss of $22.5M ($0.92/share) vs $10.0M loss ($0.56) YoY; R&D spend $19.7M (up from $9.1M).
- Cash and securities $194.8M at Jan 31, 2022, down from $248.9M at Apr 30, 2021.
- Initiated Phase 3 KONFIDENT trial for KVD900 on-demand HAE treatment; data expected H2 2023.
- Phase 2 KOMPLETE trial for KVD824 (prophylaxis) enrolling on track; data expected mid-2023.
- Factor XIIa inhibitor program advancing; first IND anticipated in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022003382/0000950170-22-003382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022003382/kalv-20220310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer